Anuh Pharma rallies on grant of approval of manufacturing site by WHO, Geneva
Anuh Pharma has rallied 20% to 245 on the BSE in intra-day trade after the company said World Health Organisation (WHO) Geneva approved the manufacturing site in district Thane, Boisar, Maharashtra.
“The company’s Maharashtra site found in compliance to WHO good manufacturing practices (GMPs) for Pyrazinamide APIMF158 and Sulfadoxine APIMF234 active pharmaceutical ingredients (APIs),” Anuh Pharma said in a release.
In another filing, the company said the same facility has granted EUGMP certificate by French National Agency for Medicines and Health Products Safety (ANSM) for products Erythromycin Ethyl Succinate and Pyrazinamide.
At 01:38 pm; the stock was up 13% at Rs 231, the top gainer among the S&P BSE Smallcap index. Around 130,000 shares changed hands on the counter against an average 2,844 shares that were traded daily in past two weeks on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd